Pharsight

Edarbi patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7157584 AZURITY Benzimidazole derivative and use thereof
May, 2025

(1 year, 2 days from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5583141 AZURITY Heterocyclic compounds and their use as angiotensin antagonists
Dec, 2013

(10 years ago)

US5958961 AZURITY Pharmaceutical composition for angiotensin II-mediated diseases
Jun, 2014

(9 years ago)

US7572920 AZURITY Benzimidazole derivative and use as a II receptor antagonist
Jan, 2025

(7 months from now)

US9066936 AZURITY Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
Mar, 2028

(3 years from now)

Edarbi is owned by Azurity.

Edarbi contains Azilsartan Kamedoxomil.

Edarbi has a total of 5 drug patents out of which 2 drug patents have expired.

Expired drug patents of Edarbi are:

  • US5583141
  • US5958961

Edarbi was authorised for market use on 25 February, 2011.

Edarbi is available in tablet;oral dosage forms.

Edarbi can be used as treatment of hypertension.

Drug patent challenges can be filed against Edarbi from 25 February, 2015.

The generics of Edarbi are possible to be released after 26 March, 2028.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 25, 2016

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient

NCE-1 date: 25 February, 2015

Market Authorisation Date: 25 February, 2011

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

How can I launch a generic of EDARBI before it's drug patent expiration?
More Information on Dosage

EDARBI family patents

Family Patents